BI-765179 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Esophageal Squamous Cell Carcinoma (ESCC). According to GlobalData, Phase I drugs for Esophageal Squamous Cell Carcinoma (ESCC) have a 95% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BI-765179’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BI-765179 overview
BI-765179 is under development for the treatment of advanced solid tumors including non-small cell lung carcinoma (NSCLC), gastric cancer, esophageal adenocarcinoma or squamous cell carcinoma, urothelial bladder carcinoma, triple-negative breast cancer, head and neck cancer squamous cell carcinoma, cutaneous squamous cell carcinoma, cutaneous malignant melanoma, hepatocellular carcinoma, pancreatic adenocarcinoma, colorectal cancer, malignant pleural mesothelioma, cervical squamous cell cancer and ovarian carcinoma. It is administered through intravenous route. It acts by targeting CD137 and FAP.
See Also:
Boehringer Ingelheim International overview
Boehringer Ingelheim International (Boehringer), a subsidiary of CH Boehringer Sohn AG & Co KG, is a pharmaceutical company that develops, manufactures and markets pharmaceuticals, parasiticides, vaccines and therapeutics for unmet medical needs. It offers a wide range of products including human diseases, animal health care products and biopharmaceuticals. The company’s products are used for the treatment central nervous system disorders, cardiometabolic diseases, respiratory diseases, cancer, immunology, and retinal diseases among others. It also offers animal healthcare products for swine, ruminant, poultry, horses and pets among others. Boehringer is headquartered in Ingelheim, Rheinland-Pfalz, Germany.
For a complete picture of BI-765179’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
